Dawn L. Hershman
Primo N. Lara, Jr.
Primo N. Lara, Jr. and Dawn L. Hershman were elected group co-chairs-elect by the SWOG Cancer Research Network board of governors. The two will serve in that capacity until the term of the current group chair, Charles D. Blanke, ends in spring 2025. They will then begin a six-year term as SWOG’s first group co-chairs.
A new report says those considering PSA screening need such quantitative information on risks and benefits of treatment if they are to make truly informed decisions. Yet leading guidelines do not provide specific estimates of risk. The risks of adverse effects and complications from treatment for prostate cancer are substantial and continue for years after...
Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib (Jakafi) to standard tyrosine kinase inhibitor treatment for patients with chronic-phase chronic myeloid leukemia significantly increased the percentage of patients who had a molecular response deep enough to warrant discontinuing treatment. Results were presented at the European School of Haematology’s 26th Annual John...
